Corporate Presentation June Curis, Inc All Rights Reserved

Transcription

1 Corporate Presentation June 2018 Curis, Inc All Rights Reserved

2 Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company ) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as expect(s), feel(s), believe(s), will, may, anticipate(s) and similar expressions are intended to identify forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management s expectations as of the date of this presentation, and involve risks and uncertainties. Forward-looking statements herein include, but are not limited to, statements with respect to the timing and results of future clinical and pre-clinical milestones; the timing of future preclinical studies and clinical trials and results of these studies and trials; the clinical and therapeutic potential of our drug candidates; and management s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of important factors including, without limitation, risks relating to: whether any of our drug candidates will advance further in the clinical development process and whether and when, if at all, they will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether historical preclinical results will be predictive of future clinical trial results; whether historical clinical trial results will be predictive of future trial results; whether any of our drug candidate discovery and development efforts will be successful; whether any of our drug candidates will be successfully marketed if approved; our ability to achieve the benefits contemplated by our collaboration agreements; management s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; competition; and the other risk factors contained in our periodic and interim reports filed with the Securities and Exchange Commission which are available on the SEC website at You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events, except as required by law. 2

3 Oncology-Focused Biotech Mission: Innovative Medicines to Treat Cancer Effectively Strategy: Development and Expect to Commercialize Heme Cancers Targeted Drugs Immune Checkpoint Inhibitors Approved Drug Royalty Revenues CUDC-907 CA-4948 MYC IRAK4 Advanced Basal Cell Carcinoma 3

4 Treatment of Patients with Cancer Orally available small molecules Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed Heme Malignancies CUDC-907 HDAC / PI3K CA-4948 * IRAK4 Kinase MYC-altered DLBCL MYD88-altered Lymphomas Checkpoint Inhibitors CA-170 * PD-L1 / VISTA CA-327 * PDL1 / TIM3 Solid Tumors & Lymphomas Cancers Approved Erivedge ** Smoothened Advanced Basal Cell Carcinoma * Licensed from Aurigene ** Developed and marketed by Genentech (Curis receives royalty income) 4

5 CUDC-907 Phase 2 drug candidate to treat MYC-driven DLBCL Program CUDC-907 HDAC / PI3K Indication MYC-altered DLBCL Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CUDC-907 Downregulates MYC CUDC-907 is clinically active PI3K in patients with CUDC-907 relapsed/refractory DLBCL HDAC that have MYC alterations MYC HDAC Transcription 5

6 Control CUDC-907 Oral, small molecule inhibitor of HDAC & PI3K enzymes 1 Down-regulates MYC mrna and protein levels 2 Phase 1 study completed 3 Favorable safety and tolerability observed Objective responses (CRs and PRs) in patients with R/R DLBCL, including in MYC-altered tumors 4 Phase 2 trial in MYC-altered R/R DLBCL 5 Objective responses (CRs and PRs) predominately in MYC-altered tumors 6 Orphan designation in DLBCL 1. Qian et.al. Clin Cancer Res : Sun et.al. Mol Cancer Ther : Younes et.al. Lancet Oncol : Oki et.al. Haematologica : Landsburg et.al : Landsburg et.al ASH Annual Conf. (nm) HDACi CUDC-907 Ac-H3 pakt MYC BCL2 Protein levels in treated DLBCL cells PI3Ki Significant Downregulation of MYC protein 6

7 CUDC-907 Clinical Studies Summary Over 200 patients treated to date Phase 1 dose escalation: R/R lymphoma and multiple myeloma 44 patients including 9 patients with DLBCL 9 patients with DLBCL: 2 CR, 3 PR Phase 1 expansion: R/R DLBCL 16 patients treated with monotherapy: 1 CR, 3 PR 12 patients treated with CUDC rituximab: 2 CR Phase 2: R/R DLBCL 68 patients 46 with MYC+ disease status: 4 CR, 3 PR 14 with MYC- disease status: 1 response 8 with unknown MYC status: 0 response Phase 1 dose escalation: R/R solid tumors 38 patients: 11 SD Well tolerated at RP2D (60mg, 5 days on/2 days off) 7

8 MYC-altered disease has inferior outcome after chemotherapy or transplant 1,2,3 CUDC-907 Addressable Population 35% of patient with DLBCL have MYC altered disease 4 Patients are less likely to qualify or proceed to stem cell transplant or cell-based therapies 1,2 REFINE study: 2 year OS of 0% for MYC-altered relapsed/refractory DLBCL vs. 29.9% for non-myc-altered 3 ~35% Patients with MYC-altered disease Comparator No FDA approved treatment options for MYC-altered patients in any line 1. Cuccuini et al. Blood May 17;119(20): Herrera et al. Journal of Clinical Oncology. 2017;35(1): Epperla et al. Cancer. 2017;123(22): Landsburg et al. Curr Hematol Malig Rep June;11(3):

9 CUDC-907 in All DLBCL Patients by MYC Status 105 patients: durable CR and PR observed Relapsed Refractory DLBCL MYC+ MYC- / Unknown Patients Enrolled CR 8 1 PR 6 4 Objective Response Rate 23.30% 11.10% CR Rate 13.30% 2.20% Duration of Response (median) 13.7 months 14.2 months Ongoing patients (range) 6 ( months) 1 (9.2 months) 10

10 CUDC-907 Development Path and Status Registration plan to treat patients with MYC-altered DLBCL Registration path Patient population: relapsed/refractory, transplant-ineligible, MYC-altered DLBCL Objective: demonstrate durable objective response benefit Pivotal trial options: non-randomized and randomized designs developed Drug manufacture Drug substance: initial commercial-scale API manufacturing has commenced Drug product: 30mg tablet formulation, 60mg once daily on 5 / 2 schedule Status In discussion with regulatory authorities Expect to update on plans and timelines in 1H

11 CA-170 Oral, small molecule checkpoint inhibitor PDL1 and VISTA Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CA-170 * PD-L1 / VISTA Solid Tumors & Lymphomas CA-170 is the only drug candidate in clinical development that targets immune checkpoints as a CA-170 Binds Interaction Site small molecule PD1 PDL1 12

12 CA-170 is a Checkpoint inhibitor Ex-vivo and in vivo T cell activation and anti-tumor activity Rationally designed, oral small molecule Targets interaction regions in the extracellular domain Targets two non-redundant immune checkpoints: PDL1 and VISTA CA-170 binds to PDL1 and to VISTA Dose-dependent ex-vivo activation of T cells inhibited by exogenous PDL1 or by VISTA Selective: no rescue of T cells inhibited by CTLA-4, TIM3, BTLA, LAG3 Potent immune stimulatory and anti-tumor activity in vivo Activity observed in models that do not respond to anti-pd1 antibody treatment (B16F1 melanoma) B16F1 Melanoma Syngeneic Model Twice weekly administration Once daily administration vehicle vehicle anti-pd1 CA-170 (low dose) CA-170 (high dose) Days 13

13 CA-170 Phase 1 Trial Dose escalation stage Accelerated Titration Followed by 3+3 Design 50mg n = 1 100mg n = 1 200mg n = 1 400mg n = mg n = mg n = mg n = mg starting Ph1b Expansion Selected Dose Levels Back-Filled with Additional Patients Objectives Primary: Recommended Phase 2 Dose (RP2D), Safety Secondary: PK, PD, anti-cancer activity Patient Population Patients with advanced solid tumors or lymphoma Study sites in South Korea, US, Spain, UK Treatment Oral, once daily, dosing in continuous 21-day cycles Baseline Patient Characteristics (Nov 2017) Characteristics Overall n = 39 Male 21 (54%) Female 18 (46%) (median, range) Age 61 (26-86) ECOG PS 0 12 (31%) ECOG PS 1 27 (69%) (median, range) Prior Lines 7 (0-9) 14

14 Best Response % C h a by n g e RECIST/Cheson R E C T / C h e s o Criteria n (%) Mel HL NSCLC Esophageal NSCLC SSCHC RCC NSCLC NSCLC RCC NSCLC Mel SSCHN SSCHN Mel NSCLC % C h a n g e R E C IS T / C h e s o n HCC RCC HL MBC Ovarian Ovarian Panc Ovarian CRC LDC Ovarian FL Anal CRC Ovarian Leiomyosarcoma CA-170 SITC Conference Phase 1 Clinical Activity mg GROUP 1 - naïve to ICI therapy - approved PD(L)1 tumor type GROUP 2 - naïve to ICI therapy - not approved PD(L)1 tumor type GROUP 3 - received prior ICI therapy - all tumor types avg 47 days on treatment avg 112 days on treatment * Ongoing patients 16

15 CA-170 Development Status Opportunity to achieve clinical benefit in multiple trials Phase 1 dose escalation Cohort of 900mg BID dosing completed Immunotherapy treatment-naïve patients Phase 2 trial ongoing in India Immunotherapy treatment-naïve patients from selected cancer types Patients with no more than 3 prior treatment regimens Evaluating potential trial options in VISTA-expressing subpopulation Opportunity in NSCLC, gastric, breast and potentially others cancer types 17

16 CA-4948 Oral, small molecule inhibitor of IRAK4 Program CA-4948 * IRAK4 Kinase Indication MYD88-altered Lymphomas Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed CA-4948 Inhibits IRAK4 TLR CA-4948 has the potential to benefit patients with MYD88-altered lymphomas MYD88 IRAK4 CA-4948 NFkB Transcription 19

17 Prevalence of Oncogenic MYD88 Mutations Indication MYD88-L265P Diffuse Large B-cell Lymphoma (ABC-DLBCL) 15-29% Immune-privileged DLBCL (IP-DLBCL) 50-80% Waldenstrom s Macroglobulinemia (WM) 95-97% Lymphoplasmacytic Lymphoma (LPL) 79% Splenic Marginal Zone Lymphoma (SMZL) 6-10% Mucosa-Associated Lymphoid Tissue (MALT) 9% Chronic Lymphocytic Leukemia (CLL) 2.9% 1. Ngo VN et al. 2011; Nature 470(7332): Kraan et al., 2013; Blood Cancer J. 3:e Treon S et al. 2018; Br J Haematol 180(3): Baer C et al. 2017; Leukemia 31(6): Martinez-Lopez A et al., 2015; Am J Surg Pathol 39(5):

18 CA-4948 Phase 1 Lymphoma Trial Summary Phase 1 open label dose escalation and expansion study of CA-4948 in patients with relapsed/refractory non-hodgkin lymphoma Dose escalation and expansion trial Patients: non-hodgkin lymphoma, including Waldenström macroglobulinemia Dose escalation: standard 3+3 design Dose expansion: treat patients at RP2D (or MTD) Patients with MYD88 mutations Patients with TLR pathway alterations Objectives: Primary: safety and tolerability, DLTs, MTD, PK Secondary: PD effects, RP2D and measurement of anti-cancer activity 23

19 Treatment of Patients with Cancer Orally available small molecules Program Indication Stage of Development Preclinical Phase 1 Phase 2 Phase 3 Marketed Heme Malignancies CUDC-907 HDAC / PI3K CA-4948 * IRAK4 Kinase MYC-altered DLBCL MYD88-altered Lymphomas Checkpoint Inhibitors CA-170 * PD-L1 / VISTA CA-327 * PDL1 / TIM3 Solid Tumors & Lymphomas Cancers Approved Erivedge ** Smoothened Advanced Basal Cell Carcinoma * Licensed from Aurigene ** Developed and marketed by Genentech (Curis receives royalty income) 24

20 Projected Milestones CUDC-907 Updated regulatory path 1H 2018 CA-170 Updated clinical results mid Q Phase 1 & Phase 2 trials CA-4948 Phase 1 dose escalation data 2H 2018 CA-327 IND filing 2H

21 Summary of Financials As of March 31, 2018 as of Mar 31 Cash & Marketable Securities $48.5M Basic Shares Outstanding 33.1M Fully Diluted Shares Outstanding 36.6M Note: Fully Diluted Shares = 33.1M basic shares + 3.5M options 26

22 END